Should I buy or sell MiMedx Group stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks .

What is MiMedx Group's stock price target for 2024?

4 Wall Street analysts have issued 12-month target prices for MiMedx Group's shares. Their MDXG share price targets range from $11.00 to $14.00. On average, they predict the company's share price to reach $12.25 in the next year. This suggests a possible upside of 94.8% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts .

How have MDXG shares performed in 2024?

MiMedx Group's stock was trading at $8.77 on January 1st, 2024. Since then, MDXG shares have decreased by 28.3% and is now trading at $6.29. View the best growth stocks for 2024 here .

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our MDXG earnings forecast .

How can I listen to MiMedx Group's earnings call?

MiMedx Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) released its earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. The business had revenue of $86.83 million for the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a trailing twelve-month return on equity of 41.12%.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.11%) and Register Financial Advisors LLC (0.02%). Insiders that own company stock include Mark Graves, Peter M Carlson, Ricci S Whitlow, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends .

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MDXG

MiMedx Group (MDXG) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free MDXG Stock Alerts

$6.29

+0.13 (+2.11%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.10
▼
$6.30
50-Day Range: $6.16
▼
$8.63
52-Week Range: $3.37
▼
$9.27

Volume: 691,192 shs
Average Volume: 763,872 shs
Market Capitalization: $924.38 million

P/E Ratio: 19.66
Dividend Yield: N/A
Price Target: $12.25

Get MiMedx Group alerts:

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 94.8% Upside
$12.25 Price Target
Short Interest: Healthy
4.98% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: Selling Shares
$409,378 Sold Last Quarter
Proj. Earnings Growth: 42.42%
From $0.33 to $0.47 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

223rd out of 918 stocks

Surgical & Medical Instruments Industry

28th out of 96 stocks

3.5

Analyst's Opinion

Consensus Rating
MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
MiMedx Group has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.98% of the float of MiMedx Group has been sold short.
Short Interest Ratio / Days to Cover
MiMedx Group has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in MiMedx Group has recently decreased by 6.16%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MiMedx Group does not currently pay a dividend.
Dividend Growth
MiMedx Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDXG.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for MiMedx Group this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MiMedx Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $409,378.00 in company stock.
Percentage Held by Insiders
19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for MiMedx Group are expected to grow by 42.42% in the coming year, from $0.33 to $0.47 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MiMedx Group is 19.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of MiMedx Group is 19.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Book Value per Share Ratio
MiMedx Group has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDXG Stock News Headlines

April 18, 2024 | fool.com

MiMedx Group (NASDAQ: MDXG)

April 16, 2024 | globenewswire.com

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 13, 2024 | wsj.com

MiMedx Group Inc.

March 29, 2024 | stockhouse.com

MIMEDX Provides Update on AXIOFILL® Request for Designation ("RFD") from FDA

March 27, 2024 | msn.com

MiMedx slips as FDA reaffirms position on Axiofill

March 27, 2024 | finance.yahoo.com

MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

March 22, 2024 | investing.com

MiMedx secures exclusive rights to wound care product

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 21, 2024 | markets.businessinsider.com

Northland Securities Keeps Their Buy Rating on MiMedx Group (MDXG)

March 21, 2024 | finance.yahoo.com

Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gain

March 20, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)

March 20, 2024 | globenewswire.com

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

March 16, 2024 | finance.yahoo.com

MDXG Apr 2024 7.500 call

March 13, 2024 | finance.yahoo.com

MIMEDX Introduces E-Commerce and Account Management Platform

March 12, 2024 | msn.com

Geron slips as FDA reviews blood cancer therapy ahead of AdCom meeting

March 4, 2024 | finance.yahoo.com

MIMEDX Announces Appointment of Two New Independent Directors

March 1, 2024 | finanznachrichten.de

MiMedx Group, Inc: MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

March 1, 2024 | markets.businessinsider.com

Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know

March 1, 2024 | finance.yahoo.com

MiMedx Group Full Year 2023 Earnings: EPS Beats Expectations

March 1, 2024 | finance.yahoo.com

MiMedx Group, Inc.'s (NASDAQ:MDXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

February 29, 2024 | finance.yahoo.com

MDXG: Another Beat & Raise

February 29, 2024 | markets.businessinsider.com

MiMedx Group: Strong Q4 Performance and Promising Growth Prospects Justify Buy Rating

February 29, 2024 | finance.yahoo.com

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Earnings Call Transcript

February 28, 2024 | washingtonpost.com

MiMedx: Q4 Earnings Snapshot

February 28, 2024 | finance.yahoo.com

MiMedx Group Inc (MDXG) Reports Strong Year-Over-Year Sales Growth and Net Income Surge in Q4 ...

February 28, 2024 | finance.yahoo.com

MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results

See More Headlines

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:MDXG
CUSIP: N/A
CIK: 1376339
Web: www.mimedx.com
Phone: (770) 651-9100
Fax: 678-384-6741
Employees: 895
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.25
High Stock Price Target: $14.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +96.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.32
Trailing P/E Ratio: 19.50
Forward P/E Ratio: 18.91
P/E Growth: N/A
Net Income: $58.23 million
Net Margins: 14.49%
Pretax Margin: 9.53%
Return on Equity: 41.12%
Return on Assets: 6.04%

Debt

Debt-to-Equity Ratio: 0.34
Current Ratio: 3.57
Quick Ratio: 3.11

Sales & Book Value

Annual Sales: $321.48 million
Price / Sales: 2.85
Cash Flow: $0.19 per share
Price / Cash Flow: 33.66
Book Value: $0.98 per share
Price / Book: 6.37

Miscellaneous

Outstanding Shares: 146,960,000
Free Float: 117,713,000
Market Cap: $917.03 million
Optionable: Optionable
Beta: 1.32

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. William F. Hulse IV (Age 50)
General Counsel & Chief Administrative Officer
Comp: $677.36k
Dr. Robert Benjamin Stein M.D. (Age 73)
Ph.D., President of Regenerative Medicine & Biologics Innovation
Comp: $639.28k
Mr. Joseph H. Capper (Age 60)
CEO & Director
Mr. Douglas C. Rice CPA (Age 58)
Chief Financial Officer
Mr. Scott M. Turner (Age 58)
Senior Vice President of Operations & Procurement
Comp: $493.98k
Mr. Matthew M. Notarianni
Head of Investor Relations
Mr. Mark P. Graves (Age 58)
Senior VP & Chief Compliance Officer
Hilary Dixon
Vice President of Investor Relations & Corporate Strategic Communications
Ms. Kate Surdez
Chief Human Resources Officer
Dr. David H. Mason Jr. (Age 77)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings or view top-rated stocks.
What is MiMedx Group's stock price target for 2024?: 4 Wall Street analysts have issued 12-month target prices for MiMedx Group's shares. Their MDXG share price targets range from $11.00 to $14.00. On average, they predict the company's share price to reach $12.25 in the next year. This suggests a possible upside of 94.8% from the stock's current price.
View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts.
How have MDXG shares performed in 2024?: MiMedx Group's stock was trading at $8.77 on January 1st, 2024. Since then, MDXG shares have decreased by 28.3% and is now trading at $6.29.
View the best growth stocks for 2024 here.
When is MiMedx Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our MDXG earnings forecast.

How can I listen to MiMedx Group's earnings call?: MiMedx Group will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were MiMedx Group's earnings last quarter?: MiMedx Group, Inc. (NASDAQ:MDXG) released its earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. The business had revenue of $86.83 million for the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a trailing twelve-month return on equity of 41.12%.
Who are MiMedx Group's major shareholders?: MiMedx Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.11%) and Register Financial Advisors LLC (0.02%). Insiders that own company stock include Mark Graves, Peter M Carlson, Ricci S Whitlow, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends.
How do I buy shares of MiMedx Group?: Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MiMedx Group (MDXG) Stock Price, News & Analysis

MiMedx Group MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MiMedx Group Stock (NASDAQ:MDXG)

MDXG Stock Price History

MDXG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MDXG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™